Literature DB >> 25711325

Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

A J Rodger1, F C Lampe, A E Grulich, M Fisher, G Friedland, N Phanuphak, J R Bogner, L C Pereira, C Rietmeijer, W Burman, A N Phillips.   

Abstract

OBJECTIVES: A proportion of HIV-positive people have condomless sex. Antiretroviral treatment (ART) reduces infectiousness, but a substantial proportion of HIV-diagnosed people are not yet on ART. We describe baseline self-reported risk behaviours in ART-naïve Strategic Timing of AntiRetroviral Treatment (START) trial participants.
METHODS: All START participants completed a risk behaviour questionnaire. Data were collected on sociodemographics, lifestyle factors, health and wellbeing status and clinical status. Recent sexual behaviour and HIV transmission beliefs in the context of ART were also assessed. The primary interest was in condomless sex with serodifferent partners (CLS-D) in the past two months.
RESULTS: A total of 4601 of 4685 HIV-positive participants (98%) completed the questionnaire [2559 men who have sex with men (MSM), 803 heterosexual men and 1239 women]. Region of recruitment was Europe/Israel, 33%; South America/Mexico, 25%; Africa, 22%; other, 21%. Median age was 36 years [interquartile range (IQR) 29, 44 years]. Forty-five per cent reported white ethnicity and 31% black ethnicity. Two per cent had HIV viral load < 50 HIV-1 RNA copies/mL. Seventeen per cent (767 of 4601) reported CLS-D; 20% of MSM compared with 10% of heterosexual men and 14% of women. MSM were also more likely to report multiple CLS-D partners. Possible risk limitation measures (reported by more than half of those who had CLS-D) were seropositioning (receptive anal CLS-D only) or withdrawal (insertive anal CLS-D always without ejaculation). CLS-D was more commonly reported by participants from South America/Mexico and North America compared with Europe; among heterosexual men and women CLS-D was also more commonly reported among participants from Africa compared with Europe. Knowledge of ART impact on transmission risk was low.
CONCLUSIONS: A substantial minority recruited to the START study reported CLS-D at baseline. CLS-D reporting was higher in MSM than heterosexuals and varied significantly according to region of recruitment. A substantial proportion of MSM reporting CLS-D appear to take transmission risk limitation measures.
© 2015 British HIV Association.

Entities:  

Keywords:  HIV; condomless sex; heterosexual; men who have sex with men; transmission

Mesh:

Year:  2015        PMID: 25711325      PMCID: PMC4341939          DOI: 10.1111/hiv.12235

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  29 in total

1.  Testing rates for sexually transmitted infections among HIV-infected men who have sex with men attending two different HIV services.

Authors:  Richard Teague; Anne Mijch; Christopher K Fairley; Mohsin Sidat; Kerrie Watson; Kerri Boyd; Marcus Y Chen
Journal:  Int J STD AIDS       Date:  2008-03       Impact factor: 1.359

2.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

3.  Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney.

Authors:  Paul Van de Ven; Limin Mao; Andrea Fogarty; Patrick Rawstorne; June Crawford; Garrett Prestage; Andrew Grulich; John Kaldor; Susan Kippax
Journal:  AIDS       Date:  2005-01-28       Impact factor: 4.177

4.  Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial.

Authors:  William Burman; Birgit Grund; Jacqueline Neuhaus; John Douglas; Gerald Friedland; Edward Telzak; Robert Colebunders; Nicholas Paton; Martin Fisher; Cornelis Rietmeijer
Journal:  J Acquir Immune Defic Syndr       Date:  2008-10-01       Impact factor: 3.731

Review 5.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.

Authors:  Suzanna Attia; Matthias Egger; Monika Müller; Marcel Zwahlen; Nicola Low
Journal:  AIDS       Date:  2009-07-17       Impact factor: 4.177

6.  Unprotected anal intercourse, risk reduction behaviours, and subsequent HIV infection in a cohort of homosexual men.

Authors:  Fengyi Jin; June Crawford; Garrett P Prestage; Iryna Zablotska; John Imrie; Susan C Kippax; John M Kaldor; Andrew E Grulich
Journal:  AIDS       Date:  2009-01-14       Impact factor: 4.177

Review 7.  The global epidemic of HIV infection among men who have sex with men.

Authors:  Frits van Griensven; Jan Willem de Lind van Wijngaarden; Stefan Baral; Andrew Grulich
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

8.  Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men.

Authors:  Julie Fox; Peter J White; Neil Macdonald; Jonathan Weber; Myra McClure; Sarah Fidler; Helen Ward
Journal:  HIV Med       Date:  2009-05-05       Impact factor: 3.180

9.  Sexual risk behaviors of HIV-positive, HIV-negative, and serostatus-unknown Black men who have sex with men and women.

Authors:  Jennifer L Lauby; Gregorio A Millett; Archana Bodas LaPollo; Lisa Bond; Christopher S Murrill; Gary Marks
Journal:  Arch Sex Behav       Date:  2008-10

Review 10.  Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis.

Authors:  Nicole Crepaz; Gary Marks; Adrian Liau; Mary M Mullins; Latrina W Aupont; Khiya J Marshall; Elizabeth D Jacobs; Richard J Wolitski
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

View more
  7 in total

1.  Event-level analysis of alcohol consumption and condom use in partnership contexts among men who have sex with men and transgender women in Lima, Peru.

Authors:  Jeanne R Delgado; Eddy R Segura; Jordan E Lake; Jorge Sanchez; Javier R Lama; Jesse L Clark
Journal:  Drug Alcohol Depend       Date:  2016-11-03       Impact factor: 4.492

2.  Correlates of Unknown HIV Status Among MSM Participating in the 2014 American Men's Internet Survey (AMIS).

Authors:  S M Traynor; A M Brincks; D J Feaster
Journal:  AIDS Behav       Date:  2018-07

3.  Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison.

Authors:  Fiona C Lampe; Alison J Rodger; William Burman; Andrew Grulich; Gerald Friedland; Wafaa El Sadr; James Neaton; Giulio M Corbelli; Sean Emery; Jean Michel Molina; Chloe Orkin; Jose Gatell; Jan Gerstoft; Kiat Ruxrungtham; Monica Barbosa de Souza; Andrew N Phillips
Journal:  AIDS       Date:  2019-12-01       Impact factor: 4.177

4.  Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status.

Authors:  Fiona C Lampe
Journal:  AIDS       Date:  2016-07-17       Impact factor: 4.177

5.  Condomless sex in HIV-diagnosed men who have sex with men in the UK: prevalence, correlates, and implications for HIV transmission.

Authors:  Marina Daskalopoulou; Alison J Rodger; Andrew N Phillips; Lorraine Sherr; Jonathan Elford; Jeffrey McDonnell; Simon Edwards; Nicky Perry; Ed Wilkins; Simon Collins; Anne M Johnson; William J Burman; Andrew Speakman; Fiona C Lampe
Journal:  Sex Transm Infect       Date:  2017-07-05       Impact factor: 3.519

6.  Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model.

Authors:  Juan Berenguer; Javier Parrondo; Raphael J Landovitz
Journal:  PLoS One       Date:  2020-07-20       Impact factor: 3.752

7.  Initiation of antiretroviral therapy with integrase strand-transfer inhibitor-based regimens and reduction of the risk of horizontal transmission of HIV-1.

Authors:  Juan Berenguer; Javier Parrondo; Raphael J Landovitz
Journal:  EClinicalMedicine       Date:  2019-10-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.